The Nova Scotia Health Innovation Hub has selected Medable’s decentralised clinical trial (DCT) platform to improve care accessibility for remote oncology patients in rural Nova Scotia, Canada.
This partnership aims to enhance patient access and trial diversity across the country.
Go deeper with GlobalData
Nova Scotia Health and Medable are collaborating on a pilot study for two years to improve access to clinical trials for oncology patients who live in rural areas and face challenges in accessing follow-up care.
Patients can use Total Consent Management and Televisit solutions, plus other services from Medable, to speak with a physician from their home.
Additionally, the new strategy is expected to empower primary care providers (PCPs) to be more involved with their patients after trials through a shared care model, which will be supported by DCT technologies.
See Also:
Nova Scotia Health physician Dr Ali Imran said: “We face numerous challenges to providing holistic care, including remote parts of Nova Scotia, difficulty in recruiting diverse patients, and a shortage of clinical researchers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“With Medable, my patients will continue to get the best care, wherever they live.”
Nova Scotia Health, which conducts nearly 400 clinical trials annually, launched its two-year pilot study of differentiated thyroid cancer patients and their follow-up care after treatment in January.
The study involved the Total Consent Management solution on the Medable platform.
Medable co-founder and CEO Michelle Longmire said: “Our technologies will empower a shared care model where PCPs will provide long-term oncology monitoring and care that was previously only possible through specialists, to the detriment of patient experience and outcomes.
“The potential benefits are vast, from improved prevention of cancer recurrence to increased diversity in clinical research.”
Last month, MedAble announced a collaboration with non-profit Every Cure for conducting global, remote clinical trials for drug repurposing candidates.
